Living systematic review of 41 RCTs (15,049 patients) in solid tumours: adding checkpoint inhibitors to radiotherapy did not significantly improve OS (HR 0.88, 95% CI 0.75–1.02; 28 trials), but did excluding glioblastoma (HR 0.83); PFS HR 0.80, EFS HR 0.73.
Meta-analysisn = 15,049
Tomassen et al. The survival impact of combining radiotherapy and immune checkpoint inhibitors in patients with solid tumors: A systematic review and living meta-analysis of randomized controlled trials